- Artificial pancreas systems are safe and effective for insulin delivery and glycemic control, including children, according to a pair of studies presented at the American Diabetes Association conference.
Why this matters
- The technology appears to be on the cusp of approval.
- In 1 study, 6-month outcomes showed that a closed-loop control system bested a sensor-augmented pump therapy for time-in-target range by 11%.
- Closed-loop control also reduced HbA1c by 0.33% more and mean glucose by 13.
- It was also tied to a decrease in hyperglycemia
- 100% of participants (ages 14-71 years) completed the trial and were still using the system at 6 months.
- Benefit seen in first month and sustained.
- In a French study comparing 24-hour use of a closed-loop system vs nighttime use only, the 30 children (ages 6-12 years) with type 1 diabetes in the trial had 80% time-in-range with nighttime use.
- These findings are interim but suggest limited risk for nighttime hypoglycemia.
- Data were presented without peer review at a conference and are preliminary for study 2.